FOR IMMEDIATE RELEASE DATE: March 25, 2025 Contact: Lisa Owens, 210-601-6647 With continued global expansion plans, NEXT Oncology is one of the largest Phase 1 Cancer Trial organizations in the world. (SAN ANTONIO, TX) March 25, 2025 ––NEXT Oncology has opened its seventh cancer care center in Houston, Texas as part of the company’s global growth initiative. NEXT – Houston, …
NEXT Oncology Moves Cancer Research Forward
NEXT Oncology, a Phase 1 Clinical Trial organization with six locations around the world, played a significant role in moving cancer research forward at the recent American Society of Clinical Oncology (ASCO) meeting in Chicago. Clinical investigators from NEXT locations around the world presented 25 abstracts, posters and presentations on the status of ongoing Phase 1 clinical trials at NEXT …
NEXT Oncology and OncoBay Clinical Collaborate on Six Phase 1 Clinical Trials
FOR IMMEDIATE RELEASE DATE: April 22, 2024 Contact: Lisa Owens, 210-601-6647 (SAN ANTONIO, TX and RALEIGH, NC) April 22, 2024 ––NEXT Oncology, a Phase 1 Clinical Trial organization with six locations around the world, and OncoBay Clinical, a leading oncology-focused full-service CRO, are collaborating on six Phase 1 Clinical trials in 10 study site locations globally to advance OncoBay’s innovative …
NEXT Oncology and MediLink Team Up on Phase 1 Clinical Trial
FOR IMMEDIATE RELEASE DATE: October 9, 2023 Contact: Lisa Owens, 210-601-6647 NEXT Oncology and MediLink Therapeutics Take “Team Approach” to Next Level on Phase 1 First in Human Clinical Trial in San Antonio (SAN ANTONIO, TX and CAMBRIDGE, MA) October 9, 2023 –– MediLink Therapeutics and NEXT Oncology are collaborating on a Phase 1 First in Human Clinical trial for …
Video: Expanded Phase 1 Program to the Dallas Area
In this video hosted by Oncology Tube, Anthony Tolcher, MD, discusses Cancer Drug Research: Expanded Phase 1 Program to the Dallas Area. iFrame is not supported!
SA cancer research company entering Dallas market as it eyes more U.S., European expansion
A cancer research company based in San Antonio is entering the Dallas market as it eyes more U.S. and European expansion… Read the full article at the San Antonio Business Journal.
NEXT Oncology Expands Phase I Program to Dallas Area
Expansion makes new break-through anticancer therapies closer to home for more Texans (DALLAS) April 12, 2023 –– Internationally known cancer researcher, Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, continues to increase access to world-class Phase I cancer research and the latest in new agents and anticancer treatments with the opening of NEXT Oncology – Dallas. NEXT Dallas is …
Grand Opening of joint venture brings access to proprietary Phase I program to more patients
NEXT-Virginia Opens Phase I Clinical Research Clinic for Oncology Patients in collaboration with Virginia Cancer Specialists. (SAN ANTONIO) January 9, 2023 –– Dr. Alexander I. Spira of Virginia Cancer Specialists (VCS) and Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, are pleased to announce the grand opening of their joint venture, NEXT Virginia, on January 12 to expand access to …
Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors
Multi-center Phase 1/2 study to evaluate safety and efficacy of TT-816, an oral CB2 receptor antagonist acting as an immune checkpoint inhibitor while promoting T cell infiltration of cold tumors and stimulating NK cell tumor killing – Cannabinoid CB2 receptors are found in many difficult-to-treat cancers, including lung, renal, and ovarian cancers – Inhibiting CB2 receptors has the potential to …
The Theresa Mays Endowed Merit Award Established for Promising Investigators Holding a PharmD Degree
(SAN ANTONIO) November 1, 2022 –– The Theresa Mays Endowed Merit Award has been established to promote the education and advancement of oncology research for pharmacists. The award has been established with the support of friends and colleagues to recognize the life and legacy of Theresa Mays, BS, PharmD, BCOP, FASHP, and Vice President of Investigational Drug Services at NEXT …